John Byrd

Image
John Byrd in whitecoat

John Byrd

Title
Professor
Address
B302 Starling Loving Hall
Email Address
Phone Number

Education

  • 1991, MD, University Of Arkansas
  • 1987, BA, with Distinction, Hendrix College, Chemistry

Honors

  • Best Doctors in America, 2012 - 2012
  • Richard L. Schilsky CALGB Achievement Award, 2010 - 2010
  • Elected Member, Henry Kunkel Society, 2009
  • NCI, CTEP Michaele C. Christian Oncology Development Lectureship and Award, 2009
  • Distinguished Scholar Award, 2008
  • AAAS Fellow, 2007
  • America's Best Doctors, 2007
  • The Don V. Unverferth Award, 2007
  • Stohlman Scholar Award, 2006
  • America's Best Doctors, 2005
  • Elected Member, 2005
  • William Crosby Superiority in Research Award, 2001
  • Army Meritous Service Medal with Silver Clover, 2001
  • Army Meritous Service Medal with Bronze Clover, 2000
  • Army Meritous Service Medal, 1998
  • Fellow of the Year, 1997
  • Kimmel Scholar, 1997
  • AACR Research Course Scholarship, 1996
  • American Society of Hematology Travel Award, 1996
  • General Erskine Award, 1994
  • Senior Resident of the Year, 1994
  • Army Commendation Medal, 1994
  • Army Achievement Medal, 1993
  • Recipient, Senior Buchanan Key, 1991
  • AOA, 1990
  • Barton Scholar, 1989 - 1991
  • Member, 1985
  • Recipient, Dorothy Snyder Scholarship, 1983 - 1987

Journal Articles

  • Blum KA, Jung SH, Johnson JL, Lin TS, His ED, Lucas DM, Byrd JC, Cheson BD, Bartlett NL Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism Annals of Oncology. 2010 Nov; 21(11):2246-2254.
  • Benson Jr DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, and Caligiuri MA The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody Blood. 2010 Sep; 116(13):2286-2294.
  • Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd, JC, Johnson AJ Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals Blood. 2010 Sep; 116(12):2078-2088.
  • Blum W, Phelps MA, KlisovicRB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, Grever MR Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 2010 Jul; 95(7):1098-1105.
  • Hertlein,Erin; Wagner,Amy,J; Jones,Jeffrey; Lin,Thomas,S; Maddocks,Kami,J; Towns,William,H; Goettl,Virginia,M; Zhang,Xiaoli; Jarjoura,David; Raymond,Chelsey,A; West,Derek,A; Croce,Carlo,M; Byrd,John,C; Johnson,Amy,J 17-DMAG targets the nuclear factor-kappa B family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition Blood. 2010 Jul; 116(1):45-53.
  • Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos LA, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, and Byrd JC Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation BRITISH JOURNAL OF HAEMATOLOGY. 2010 Jul; 150(2):189-195.
  • Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, and Muthusamy N FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma Clinical Cancer Research. 2010 Jun; 16(12):3182-3192.
  • Kay NE, Wu W, Kabat B, Laplant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia Cancer. 2010 May; 116(9):2180-2187.
  • Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford, Jr, R, Rader R, Muthusamy N, Johnson AJ*, Byrd JC*. Co-senior author Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway Blood. 2010 Apr; 115(13):2619-2629.
  • Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia Cancer Cell. 2010 Apr; 17(4):333-347.
  • Butchar JP, Mehta P, Justiniano SE, Guenterberg KD, Kondadasula SV, Mo X, Chemudupati M, Kanneganti TD, Amer A, Muthusamy N, Jarjoura D, Marsh CB, Carson, WE 3rd, Byrd JC, Tridandapani S Reciprocal Regulation of Activating and Inhibitory Fc gamma Receptors by TLR7/8 Activation: Implications for Tumor Immunotherapy Clinical Cancer Research. 2010 Apr; 16(7):2065-2075.
  • Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2010 Apr; 107(16):7473-7478.
  • Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S Genome wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma Blood. 2010 Apr; 10 1182.
  • Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, Andritsos LA, Blum KA, Flynn JM, Jones JA, Byrd JC Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease British Journal of Haematology. 2010 Mar; 148(5):754-759.
  • Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson, Jr DM, Roda JM, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy N*, Byrd JC*. Co-senior author. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody Blood. 2010 Feb; 115(6):1204-1213.
  • Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut, EH Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders Journal of Clinical Oncology. 2010 Jan; 28(3):418-423.
  • Byrd,John,C; Kipps,Thomas,J; Flinn,Ian,W; Castro,Januaro; Lin,Thomas,S; Wierda,William; Heerema,Nyla; Woodworth,James; Hughes,Steve; Tangri,Shabnam; Harris,Sarah; Wynne,Dee; Molina,Arturo; Leigh,Bryan; O'Brien,Susan Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia Blood. 2010 Jan; 115(3):489-495.
  • Awan,Farrukh,T; Johnson,Amy,J; Lapalombella,Rosa; Hu,Weihong; Lucas,Margaret; Fischer,Beth; Byrd,John,C Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia Leukemia & Lymphoma. 2010 Jan; 51(1):27-38.
  • Koh CG, Zhang X, Liu S, Golan S, Yu B, Yang X, Guan J, Jin Y, Talmon Y, Muthusamy N, Chan KK, Byrd JC, Lee RJ, Marcucci G, Lee LJ Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing JOURNAL OF CONTROLLED RELEASE. 2010 Jan; 141(1):62-69.
  • Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, LaCasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos JP Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 Journal of Clinical Oncology. 2009 Dec; 36(27):6101-6108.
  • Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia Leukemia & Lymphoma. 2009 Dec; 12(50):1958-1963.
  • Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Adritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease Journal of Clinical Oncology. 2009 Dec; 27(35):6012-6018.
  • Blum K, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC Phase II study of the histone deacetylase inhibitor MGC0103 in patients with previously treated chronic lymphcytic leukaemia. British Journal of Haematology. 2009 Nov; 147(4):507-514.
  • Byrd JC Hunting for the Achilles' heel of CLL Blood. 2009 Nov; 20(114):4324.
  • Chen SS, Sherman MH, Herlein E, Johnson AJ, Teitell MA, Byrd JC*, Plass C*. Co-senior author Epigenetic alterations in a murine model for chronic lymphcytic leukemia. Cell Cycle. 2009 Nov; 8(22):3663-3667.
  • Chen SS, Raval A, Johnson AJ, Herlein E, Liu TH, Jin VX, Sherman JH, Liu SH, Dawson DW, Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC*, Plass C*. Co-senior author Epigenetic changes during disease progression in a murine model of human chronic lymphcytic leukemia PNAS. 2009 Aug; 106(32):13433-13438.
  • Garzon R, Liu S, Fabbri M, Liu A, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N Havelang V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreef M, Bloomfield CD, Byrd JC, Chan K, Wu, LC, Croce CM, Marcucci G MicroRNA -29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Blood. 2009 Jun; 113(25):6411-6418.
  • Lucas DM, Edwards RB, Lozanski G, West DA, Jungook DS, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema MA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR The Novel plant-derived agent selvestrol has B-cell selective activity in chronic Lymphocytic leukemia and acute lymphblastic leukemia in vitro and in vivo. Blood. 2009 May; 113(19):4656-4666.
  • Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA Validation of an LC-MS based approach for profiling histones in chronic Lymphocytic leukemia Proteomics. 2009 Mar; 5 1197-1206.
  • Phelps, MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Booker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopriodol in relapsed chronic lymphocytic leukemia Blood. 2009 Mar; 12(113):2637-2645.
  • Awan FT; Kay NE; Davis ME; Wu W; Geyer SM; Leung N; Jelinek DF; Tschumper RC; Secreto CR; Lin TS; Grever MR; Shanafelt TD; Zent CS; Call TG; Heerema NA; Lozanski G; Byrd JC; Lucas DM Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood. 2009 Jan; 113(3):535.
  • Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, Ferketich AK, Lai R, Lucas DM, Porcu P, Blum KA, Byrd JC, Baiocchi RA Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma MAbs. 2009 Jan; 1 31-40.
  • Joshi T; Ganesan LP; Cheney C; Ostrowski MC; Muthusamy N; Byrd JC; Tridandapani S The PtdIns 3-kinase/Akt pathway regulates macrophage-mediated ADCC against B cell lymphoma. Plos ONE. 2009 Jan; 4(1):e4208.
  • Christian BA, Grever MR, GByrd JC, Lin TS, Byrd JC Flavopiridol in chronic lymphocytic leukemia: A consise review. Clinical Lymphoma Myeloma. 2009 Jan; 3(9):S179-185.
  • Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE, Vij R, Blum W Single agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 Blood. 2009 Jan; 5(113):1002-1005.
  • Fehniger TA; Byrd JC; Marcucci G; Abboud CN; Kefauver C; Payton JE; Vij R; Blum W Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood. 2009 Jan; 113(5):1002.
  • Lin,Thomas,S; Stock,Wendy; Xu,Huiping; Phelps,Mitch,A; Lucas,Margaret,S; Guster,Sara,K; Briggs,Bruce,R; Cheney,Carolyn; Porcu,Pierluigi; Flinn,Ian,W; Grever,Michael,R; Dalton,James,T; Byrd,John,C A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia LEUKEMIA & LYMPHOMA. 2009 Jan; 50(12):1958-1963.
  • Hamadni M, Blum W, Phillips F, Elder P, Andritsos, L, Hofmeister C, O’Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation. 2009 Jan; 11(15):1422-1430.
  • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd JC, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A A critical role for phosphatase haplodefiency in the selective suppression of deletion 5q MDS by lenalidomide Proceedings for the National Academy of Science, USA. 2009 Jan; 31(406):12974-12979.
  • Shanafelt TD, Byrd JC, Laplant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. British Journal of Haematology. 2009 Jan; 146(6) 660-664.
  • Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic Lymphocytic leukaemia British Journal of Haematology. 2009 Jan; 6(144):848-855.
  • Yang X; Zhao X; Phelps MA; Piao L; Rozewski DM; Liu Q; Lee LJ; Marcucci G; Grever MR; Byrd JC; Dalton JT; Lee RJ A novel liposomal formulation of flavopiridol. International Journal Of Pharmaceutics. 2009 Jan; 365(1-2):170.
  • Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, RuppertAS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitazel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 2009 Jan; .
  • Yang X; Koh CG; Liu S; Pan X; Santhanam R; Yu B; Peng Y; Pang J; Golan S; Talmon Y; Jin Y; Muthusamy N; Byrd JC; Chan KK; Lee LJ; Marcucci G; Lee RJ Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Molecular Pharmaceutics. 2009 Jan; 6(1):221.
  • Blum, KA, Hamandani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM, Byrd JC Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma Leukemia and Lymphoma. 2009 Jan; 3(50):349-356.
  • Woyach, JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei, L, Caligiuri MA, Byrd JC A phase I/II study of rituximab and etanercept in patients with chronic Lymphocytic leukemia and small Lymphocytic lymphoma. Leukemia. 2009 Jan; .
  • Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang D, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells Blood. 2008 Jan; 13(112):5180-5189.
  • Andritsos L, Johnson AJ, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang D, Knight RD, Chen CS, Byrd JC Higher Doses of Lenalidomide Are Associated with Unacceptable Toxicity Including Life Threatening Tumor Flare in Chronic Lymphocytic Leukemia Patients Journal of Clinical Oncology. 2008 Jan; 15(26):2519-2525.
  • Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ Relative value of ZAP-70, CD38, and Immunoglobulin Mutation Status in Predicting Aggressive Disease in Chronic Lymphocytic Leukemia. Blood. 2008 Jan; 5(112):1923-1930.
  • Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug Journal of Clinical Investigation. 2008 Jan; 7(118):2427-2437.
  • Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling Cancer Research. 2008 Jan; 4(68):1204-1212.
  • Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda AW, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal-center leukemogenic selection Blood. 2008 Jan; 10(111):5101-5108.
  • Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JCer MR, Dalton JT Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule Journal of Chromatography B: Analytic Technology in Biomedical Life Science. 2008 Jan; 1-2(868):110-115.
  • Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium Blood. 2008 Jan; 6(111):3190-3199.
  • Lapalombella R, Zhao X, Triantafillou G, Yu B, Lin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Lee R , Caligiuri MA, Muthusamy N, Byrd JC A novel Raji-Burkitt’s lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents Clinical Cancer Research. 2008 Jan; 14 569-578.
  • Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum WG, Porcu P, Garzon R, Byrd JCCaligiuri MA, Chan KK, Wu LC, Marcucci G Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF- B-dependent DNA methyltransferase activity in acute myeloid leukemia Blood. 2008 Jan; 4(111):2364-2373.
  • Gowda A, Roda J, Hussain R, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Carson WE, Muthusamy N, Byrd JC IL-21 Mediates Apoptosis Through Up-Regulation of the BH3 Family Member BIM and Enhances both Direct and Antibody Dependent Cellular Cytotoxicity in Primary Chronic Lymphocytic Cells Blood. 2008 Jan; 9(111):4723-4730.
  • Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia Clinical Cancer Research. 2008 Jan; 14 3889-3895.
  • Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Vanden Burgt J, Van Laar E, Cullen M, Byrd JC, Marcucci G A Phase I Biologic Study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase I, in paients with high risk myeloidysplasia and acute myeloid leukemia Clinical Cancer Research. 2008 Jan; 14 2444-2499.
  • Klisovic RB, Stock W, Cataland S, Klisovic MI, Lui S, Blum W, Green M, Odenike O, Godley L, Vanden Burgt J, Van Laar E, Cullen M, Macleod R, Besterman JM, Reid GK, Byrd JC A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia. Clinical Cancer Research. 2008 Jan; 8(14):2444-2449.
  • Trotta R, Col JD, Yu J, Ciarlariello D, ThomasB, Zhang X, Allard II J , Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells Journal of Immunology. 2008 Jan; 181 3784-3792.
  • Pathan NI, Hariharan K, Chu P, Cheney C, Molina A, Byrd JC Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines Blood. 2008 Jan; 3(111):1594-1602.
  • Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ A novel liposomal formulation of flavopiridol International Journal of Pharmaceutics. 2008 Jan; 1-2(365):170-174.
  • Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JChelps MA Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma The Drug Monitor. 2008 Jan; .
  • Kay NE, Geyer SM, Lin TS, Call TG, Jelinek DF, Bone ND, Dewald GW, Heerema NA, Schumper RT, Smith LT, Grever MR, Byrd JC Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Significant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia Blood. 2007 Jan; 109 405-411.
  • Alinari, L; Lapalombella, R; Andritsos, L; Baiocchi, RA; Lin, TS; Byrd JC Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007 Jan; 26(25):3644-3653.
  • Knapp, Amy, R; Ren, Chen; Su, Xiaodan; Lucas, David, M; Byrd JC; Freitas, Michael, A; Parthun, Mark R Quantitative profiling of histone post-translational modifications by stable isotope labeling. Methods (San Diego, Calif.). 2007 Jan; 41(3):312-319.
  • Kay, Neil, E; Geyer, Susan, M; Call, Timothy, G; Shanafelt, Tait, D; Zent, Clive, S; Jelinek, Diane, F; Tschumper, Renee; Bone, Nancy, D; Dewald, Gordon, W; Lin, Thomas, S; Heerema, Nyla, A; Smith, Lisa; Grever, Michael, R; Byrd JC Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007 Jan; 109(2):405-411.
  • Liu, Zhongfa; Liu, Shujun; Xie, Zhiliang; Blum, William; Perrotti, Danilo; Paschka, Peter; Klisovic, Rebecca; Byrd JC; Chan, Kenneth, K; Marcucci, Guido Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic acids research. 2007 Jan; 35(5):.
  • Rawstron, A, C; Villamor, N; Ritgen, M; Bottcher, S; Ghia, P; Zehnder, J, L; Lozanski, G; Colomer, D; Moreno, C; Geuna, M; Evans, P A, S; Natkunam, Y; Coutre, S, E; Avery, E, D; Rassenti, L, Z; Kipps, T, J; Caligaris-Cappio, F; Kneba, M; Byrd JC; Hallek, M, J; et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2007 Jan; 21(5):956-964.
  • Christian, Beth, A; Grever, Michael, R; Byrd, Byrd JC; Lin, Thomas S Flavopiridol in the treatment of chronic lymphocytic leukemia. Current opinion in oncology. 2007 Jan; 19(6):573-578.
  • Cheng H, Liu Z, Blum W, Byrd JC, Klisovic R, Grever MR, Marcucci G, Chan KK Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS Journal of Chromatography B: Analyical Technology in Biomedical Life Schience. 2007 Jan; 1-2(850):206-212.
  • Byrd JC; O'Brien, Susan; Flinn, Ian, W; Kipps, Thomas, J; Weiss, Mark; Rai, Kanti; Lin, Thomas, S; Woodworth, James; Wynne, Dee; Reid, Jennifer; Molina, Arturo; Leigh, Bryan; Harris, Sarah Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Jan; 13(15 Pt 1):.
  • Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes British Journal of Hematology. 2007 Jan; 5(139):744-752.
  • Cheng, Hao; Liu, Zhongfa; Blum, William; Byrd, John, C; Klisovic, Rebecca; Grever, Michael, R; Marcucci, Guido; Chan, Kenneth K Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Jan; 850(1-2):206-212.
  • Roda JM, Byrd JC Fc RIIIa role in rituximab efficacy Blood. 2007 Jan; 110 2220.
  • Su, Xiaodan; Jacob, Naduparambil, K; Amunugama, Ravindra; Lucas, David, M; Knapp, Amy, R; Ren, Chen; Davis, Melanie, E; Marcucci, Guido; Parthun, Mark, R; Byrd JC; Fishel, Richard; Freitas, Michael A Liquid chromatography mass spectrometry profiling of histones. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Jan; 850(1-2):440-454.
  • Su, Xiaodan; Zhang, Liwen; Lucas, David, M; Davis, Melanie, E; Knapp, Amy, R; Green-Church, Kari, B; Marcucci, Guido; Parthun, Mark, R; Byrd JC; Freitas, Michael A Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry. Analytical biochemistry. 2007 Jan; 363(1):22-34.
  • Zhao, Xiaobin; Lapalombella, Rosa; Joshi, Trupti; Cheney, Carolyn; Gowda, Aruna; Hayden-Ledbetter, Martha, S; Baum, Peter, R; Lin, Thomas, S; Jarjoura, David; Lehman, Amy; Kussewitt, Donna; Lee, Robert, J; Caligiuri, Michael, A; Tridandapani, Susheela; Muthusamy, Natarajan; Byrd JC Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. 2007 Jan; 110(7):2569-2577.
  • Byrd JC; Lin, Thomas, S; Dalton, James, T; Wu, Di; Phelps, Mitch, A; Fischer, Beth; Moran, Mollie; Blum, Kristie, A; Rovin, Brad; Brooker-McEldowney, Michelle; Broering, Sarah; Schaaf, Larry, J; Johnson, Amy, J; Lucas, David, M; Heerema, Nyla, A; Lozanski, Gerard; Young, Donn, C; Suarez, Jose-Ramon; Colevas, A Dimitrios; Grever, Michael R Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007 Jan; 109(2):399-404.
  • Zhao XB, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum P, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC A Novel Engineered Anti-CD37 Small Modular Immuno Pharmaceutical (SMIP) Demonstrates Promising Preclinical Activity against B-Cell Lymphoproliferative Disorder Blood. 2007 Jan; 7(100):2569-2577.
  • Neviani, Paolo; Santhanam, Ramasamy; Oaks, Joshua, J; Eiring, Anna, M; Notari, Mario; Blaser, Bradley, W; Liu, Shujun; Trotta, Rossana; Muthusamy, Natarajan; Gambacorti-Passerini, Carlo; Druker, Brian, J; Cortes, Jorge; Marcucci, Guido; Chen, Ching-Shih; Verrills, Nicole, M; Roy, Denis, C; Caligiuri, Michael, A; Bloomfield, Clara, D; Byrd JC; Perrotti, Danilo FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of clinical investigation. 2007 Jan; 117(9):2408-2421.
  • Shah MH, Villalona-Calero MA, Marcucci G, Byrd JC, Grever MR Inhibitors and Cardiac Safety Clin Cancer Res. 2007 Jan; (13):.
  • Tanner SM, Byrd JC Advances in genome-wide CLL linkage Blood. 2007 Jan; 110(9)(1):3094-3095.
  • Motiwala, Tasneem; Majumder, Sarmila; Kutay, Huban; Smith, David Spencer; Neuberg, Donna, S; Lucas, David, M; Byrd JC; Grever, Michael; Jacob, Samson T Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Jan; 13(11):3174-3181.
  • Ali, Naeem, A; O'Brien, James M Jr; Blum, William; Byrd JC; Klisovic, Rebecca, B; Marcucci, Guido; Phillips, Gary; Marsh, Clay, B; Lemeshow, Stanley; Grever, Michael R Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer. 2007 Jan; 110(1):96-102.
  • Shanafelt, Tait, D; Lin, Thomas; Geyer, Susan, M; Zent, Clive, S; Leung, Nelson; Kabat, Brian; Bowen, Deborah; Grever, Michael, R; Byrd JC; Kay, Neil E Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007 Jan; 109(11):2291-2298.
  • Raval, Aparna; Tanner, Stephan, M; Byrd JC; Angerman, Elizabeth, B; Perko, James, D; Chen, Shih-Shih; Hackanson, Bjorn; Grever, Michael, R; Lucas, David, M; Matkovic, Jennifer, J; Lin, Thomas, S; Kipps, Thomas, J; Murray, Fiona; Weisenburger, Dennis; Sanger, Warren; Lynch, Jane; Watson, Patrice; Jansen, Mary; Yoshinaga, Yuko; Rosenquist, Richard; et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007 Jan; 129(5):879-890.
  • Grever, Michael, R; Lucas, David, M; Johnson, Amy, J; Byrd JC Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best practice & research. Clinical haematology. 2007 Jan; 20(3):545-556.
  • Grever, Michael, R; Lucas, David, M; Dewald, Gordon, W; Neuberg, Donna, S; Reed, John, C; Kitada, Shinichi; Flinn, Ian, W; Tallman, Martin, S; Appelbaum, Frederick, R; Larson, Richard, A; Paietta, Elisabeth; Jelinek, Diane, F; Gribben, John, G; Byrd JC Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Jan; 25(7):799-804.
  • Pal, Sharmistha; Baiocchi, Robert, A; Byrd JC; Grever, Michael, R; Jacob, Samson, T; Sif, Said Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. The EMBO journal. 2007 Jan; 26(15):.
  • Byrd JC, Lin TS, Dalton JT, Wu D, Fischer B, Moran M,? Blum KA, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Ramon-Suarez J, Colevas AD, Grever MR Flavopiridol Administered in a Pharmacologically Derived Schedule Is Associated with Tumor Lysis Syndrome and Marked Clinical Efficacy in Refractory, Genetically High Risk Chronic Lymphocytic Leukemia Blood. 2007 Jan; 109 399-404.
  • Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia British Journal of Hematology. 2007 Jan; 5(139):837-844.
  • Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, Klisovic R, Byrd JC, Chan KK, Marcucci G. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method Nucleic Acids Res.. 2007 Jan; (35):.
  • Blum, Kristie, A; Young, Donn; Broering, Sarah; Lucas, Margaret, S; Fischer, Beth; Lin, Thomas, S; Grever, Michael, R; Byrd JC Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Jan; 25(35):5624-5629.
  • Hussain, Syed-Rehan, A; Cheney, Carolyn, M; Johnson, Amy, J; Lin, Thomas, S; Grever, Michael, R; Caligiuri, Michael, A; Lucas, David, M; Byrd JC Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Jan; 13(7):2144-2150.
  • Blum, William; Klisovic, Rebecca, B; Hackanson, Bjoern; Liu, Zhongfa; Liu, Shujun; Devine, Hollie; Vukosavljevic, Tamara; Huynh, Lenguyen; Lozanski, Gerard; Kefauver, Cheryl; Plass, Christoph; Devine, Steven, M; Heerema, Nyla, A; Murgo, Anthony; Chan, Kenneth, K; Grever, Michael, R; Byrd, Byrd JC; Marcucci, Guido Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Jan; 25(25):3884-3891.
  • Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decatabine (5-aza-2’-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method Rapid Communications in Mass Spectrometry. 2006 Jan; 20 1117-1126.
  • Blum, Kristie, A; Johnson, Jeffrey, L; Niedzwiecki, Donna; Piro, Lawrence, D; Saven, Alan; Peterson, Bruce, A; Byrd JC; Cheson, Bruce, D; Cheson, Bruce D Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer. 2006 Jan; 107(12):2817-2825.
  • Mone, A, P; Cheney, C; Banks, A, L; Tridandapani, S; Mehter, N; Guster, S; Lin, T; Eisenbeis, C, F; Young, D, C; Byrd JC Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2006 Jan; 20(2):.
  • Raval A, Byrd JC Epigenetics in chronic lymphocytic leukemia Seminars in Oncology. 2006 Jan; 2(33):157-166.
  • Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O’Brien S, Keating MJ Phase II study of single-agent bortezomib (VELCADE®) for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia Cancer. 2006 Jan; 67 916-924.
  • Khan, Khuda, D; Emmanouilides, Christos; Benson, Don M Jr; Hurst, Deborah; Garcia, Pablo; Michelson, Glenn; Milan, Sandra; Ferketich, Amy, K; Piro, Lawrence; Leonard, John, P; Porcu, Pierluigi; Eisenbeis, Charles, F; Banks, Amy, L; Chen, Lei; Byrd JC; Caligiuri, Michael A A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Jan; 12(23):.
  • Byrd JC New drugs for chronic lymphocytic leukemia. Clinical advances in hematology & oncology : H&O. 2006 Jan; 4(3):.
  • Johnson AJ, Lucas DM, Muthusamy N, Smith L, Edwards R, DeLay M, Croce CM, Grever MR, Byrd JC Characterization of the TCL-1 transgenic mouse as a pre-clinical drug development tool for human chronic lymphocytic leukemia Blood. 2006 Jan; 108 1334-1338.
  • Willis CR, Goodrich A, Park K, Waselendo JD, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC A phase I/II study examining pentostatin chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin’s lymphoma Annals of Hematology. 2006 Jan; 85 301-307.
  • Blum W, Bolwell BJ. Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation Biology of Blood and Marrow Transplantation. 2006 Jan; 12 61-67.
  • Brena RM, Auer H, Kornacker K, Raval A, Byrd JC, Plass C Accurate quantitation of DNA methylation using Combined Bisulfite Restriction Assay (CoBRA) in combination with the Agilent™ 2100 Bioanalyzer platform Nucleic Acids Research. 2006 Jan; 3(34):.
  • Byrd JC, Lin TS, Grever M Treatment of relapsed chronic lymphocytic leukemia: old and new therapies Seminars in Oncology. 2006 Jan; 33 210-219.
  • Ganesan LP, Joshi T, Fang H, Kutala VK, Roda J, Trotta R, Lehman A, Kuppusamy P, Byrd JC, Carson WE, Caligiuri MA, Tridandapani S Fc {gamma} R-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways Blood. 2006 Jan; 108 718-725.
  • Byrd JC; Marcucci, Guido; Parthun, Mark, R; Xiao, Jim, J; Klisovic, Rebecca, B; Moran, Mollie; Lin, Thomas, S; Liu, Shujun; Sklenar, Amy, R; Davis, Melanie, E; Lucas, David, M; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj, L; Binkley, Philip; Wright, John; Chan, Kenneth, K; Grever, Michael R A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005 Jan; 105(3):959-67.
  • Marcucci, Guido; Stock, Wendy; Dai, Guowei; Klisovic, Rebecca, B; Liu, Shujun; Klisovic, Marko, I; Blum, William; Kefauver, Cheryl; Sher, Dorie, A; Green, Margaret; Moran, Mollie; Maharry, Kati; Novick, Steven; Bloomfield, Clara, D; Zwiebel, James, A; Larson, Richard, A; Grever, Michael, R; Chan, Kenneth, K; Byrd JC Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jan; 23(15):3404-11.
  • Lin, T, S; Flinn, I, W; Lucas, M, S; Porcu, P; Sickler, J; Moran, M, E; Lucas, D, M; Heerema, N, A; Grever, M, R; Byrd JC Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 Jan; 19(7):.
  • Dai, Guowei; Chan, Kenneth, K; Liu, Shujun; Hoyt, Dale; Whitman, Susan; Klisovic, Marko; Shen, Tiansheng; Caligiuri, Michael, A; Byrd JC; Grever, Michael; Marcucci, Guido Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jan; 11(8):2998-3008.
  • Lin, T, S; Penza, S, L; Avalos, B, R; Lucarelli, M, R; Farag, S, S; Byrd JC; Copelan, E A Diffuse alveolar hemorrhage following gemtuzumab ozogamicin. Bone marrow transplantation. 2005 Jan; 35(8):.
  • Lin, Thomas, S; Flinn, Ian, W; Modali, Rama; Lehman, Teresa, A; Webb, Jennifer; Waymer, Sharon; Moran, Mollie, E; Lucas, Margaret, S; Farag, Sherif, S; Byrd JC FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood. 2005 Jan; 105(1):289-91.
  • Liu, Shujun; Shen, Tiansheng; Huynh, Lenguyen; Klisovic, Marko, I; Rush, Laura, J; Ford, Jamie, L; Yu, Jianhua; Becknell, Brian; Li, Yu; Liu, Chunhui; Vukosavljevic, Tamara; Whitman, Susan, P; Chang, Kun-Sang; Byrd JC; Perrotti, Danilo; Plass, Christoph; Marcucci, Guido Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer research. 2005 Jan; 65(4):1277-84.
  • Lin, Thomas, S; Grever, Michael, R; Byrd JC Changing the way we think about chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jan; 23(18):4009-12.
  • Yu, Li; Liu, Chunhui; Vandeusen, Jeff; Becknell, Brian; Dai, Zunyan; Wu, Yue-Zhong; Raval, Aparna; Liu, Te-Hui; Ding, Wei; Mao, Charlene; Liu, Shujun; Smith, Laura, T; Lee, Stephen; Rassenti, Laura; Marcucci, Guido; Byrd JC; Caligiuri, Michael, A; Plass, Christoph Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature genetics. 2005 Jan; 37(3):265-74.
  • Byrd JC; Marcucci, Guido; Parthun, Mark R.; Xiao, Jim J.; Klisovic, Rebecca B.; Moran, Mollie; Lin, Thomas S.; Liu, Shujun; Sklenar, Amy R.; Davis, Melanie E.; Lucas, David M.; Fischer, Beth; Shank, Roshini; Tejaswi, Sooraj L.; Binkley, Philip; Wright, John; Chan, Kenneth K.; Grever, Michael R. A phase 1 and pharmacodynamic study of depsipeptide (fk228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood. 2005 Jan; 105(3):959-967.
  • Issa, Jean-Pierre J.; Byrd JC Decitabine in chronic leukemias Seminars in Hematology. 2005 Jan; 42(3, Suppl. 2):S43-S49.
  • Byrd JC; Peterson, Bercedis, L; Gabrilove, Janice; Odenike, Olatoyosi, M; Grever, Michael, R; Rai, Kanti; Larson, Richard A Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jan; 11(11):4176-81.
  • Xiao, Jim, J; Huang, Ying; Dai, Zunyan; Sadee, Wolfgang; Chen, Jiyun; Liu, Shujun; Marcucci, Guido; Byrd JC; Covey, Joseph, M; Wright, John; Grever, Michael; Chan, Kenneth K Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. The Journal of pharmacology and experimental therapeutics. 2005 Jan; 314(1):467-75.
  • Raval, Aparna; Lucas, David, M; Matkovic, Jennifer, J; Bennett, Kristi, L; Liyanarachchi, Sandya; Young, Donn, C; Rassenti, Laura; Kipps, Thomas, J; Grever, Michael, R; Byrd JC; Plass, Christoph TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jan; 23(17):3877-85.
  • Mone AP, Puhalla S, Whitman S, Baiocchi R, Cruz J, Byrd JC, Caligiuri MA, Porcu P Durable hematologic complete response and suppression of HTLV-1 viral load following Alemtuzumab in AZT/IFN refractory adult T-cell leukemia (ATL) Blood. 2005 Jan; 106 3380-3382.
  • Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC Phase I Study of Low-Dose IL-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia: No evidence of diminished cellular immune dysfunction Clinical Cancer Research. 2005 Jan; 11 8413-8417.
  • Tseng, Ping-Hui; Lin, Ho-Pi; Zhu, Jiuxiang; Chen, Kuen-Feng; Hade, Erinn M.; Young, Donn C.; Byrd JC; Grever, Michael; Johnson, Kara; Druker, Brian J.; Chen, Ching-Shih Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor Osu-03012 in overcoming imatinib mesylate resistance Blood. 2005 Jan; 105(10):4021-4027.
  • Farag, S, S; Bolwell, B, J; Elder, P, J; Kalaycio, M; Lin, T; Pohlman, B; Penza, S; Marcucci, G; Blum, W; Sobecks, R; Avalos, B, R; Byrd JC; Copelan, E High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone marrow transplantation. 2005 Jan; 35(7):.
  • Johnson, Amy J.; Smith, Lisa L.; Zhu, Jiuxiang; Heerema, Nyla A.; Jefferson, Sara; Mone, Andrew; Grever, Michael; Chen, Ching-Shih; Byrd JC A novel celecoxib derivative, Osu03012, induces cytotoxicity in primary Cll cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism Blood. 2005 Jan; 105(6):2504-2509.
  • Bolanos-Meade, Javier; Jacobsohn, David, A; Margolis, Jeffrey; Ogden, Adam; Wientjes, M Guillaume; Byrd JC; Lucas, David, M; Anders, Viki; Phelps, Michele; Grever, Michael, R; Vogelsang, Georgia B Pentostatin in steroid-refractory acute graft-versus-host disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Jan; 23(12):2661-8.
  • Flinn IW, Byrd JC, Bartlett N, Kipps TJ, Gribben J, Thomas D, Larson RA, Rai KR, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR A Phase II Study of 24-hour Continuous Infusion Flavopiridol in Chronic Lymphocytic Leukemia. Submitted for publication @Co-First Authors Leukemia Research. 2005 Jan; 29 1253-1257.
  • Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Wickham J, Davis ME, Lucas DM, Fischer B, Shank R, Binkley P, Wright J, Chan KK, Grever MR A Minimum Effective Pharmacologic Dose Finding Study of Depsipeptide (FK228) in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia Blood. 2005 Jan; 105 959-967.
  • Lin, Thomas, S; Byrd JC Monoclonal antibody therapy in lymphoid leukemias. Advances in pharmacology. 2004 Jan; 51 127-67.
  • Byrd JC; Stilgenbauer, Stephan; Flinn, Ian W Chronic lymphocytic leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2004 Jan; 163-83.
  • Blum, Kristie A.; Lozanski, Gerard; Byrd JC Adult Burkitt leukemia and lymphoma Blood. 2004 Jan; 104(10):3009-3020.
  • Rush, Laura J.; Raval, Aparna; Funchain, Pauline; Johnson, Amy J.; Smith, Lisa; Lucas, David M.; Bembea, Melania; Liu, Te-Hui; Heerema, Nyla A.; Rassenti, Laura; Liyanarachchi, Sandya; Davuluri, Ramana; Byrd JC; Plass, Christoph Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets Cancer Research. 2004 Jan; 64(7):2424-2433.
  • Mone, Andrew P.; Huang, Peng; Pelicano, Helene; Cheney, Carolyn M.; Green, Jennifer M.; Tso, J. Yun; Johnson, Amy J.; Jefferson, Sara; Lin, Thomas S.; Byrd JC Hu1d10 induces apoptosis concurrent with activation of the Akt survival pathway in human chronic lymphocytic leukemia cells. Blood. 2004 Jan; 103(5):1846-1854.
  • Lin, Thomas S.; Moran, Mollie; Lucas, Margaret; Waymer, Sharon; Jefferson, Sara; Fischer, Diane B.; Grever, Michael R.; Byrd JC Antibody therapy for chronic lymphocytic leukemia: a promising new modality Hematology-Oncology Clinics of North America. 2004 Jan; 18(4):895-913, IX, X, XI.
  • Eisenbeis, Charles, F; Grainger, Andrew; Fischer, Beth; Baiocchi, Robert, A; Carrodeguas, Lester; Roychowdhury, Sameek; Chen, Lei; Banks, Amy, L; Davis, Thomas; Young, Donn; Kelbick, Nicole; Stephens, Julie; Byrd JC; Grever, Michael, R; Caligiuri, Michael, A; Porcu, Pierluigi Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Jan; 10(18 Pt 1):6101-10.
  • Lozanski, Gerard; Heerema, Nyla A.; Flinn, Ian W.; Smith, Lisa; Harbison, Jennifer; Webb, Jennifer; Moran, Mollie; Lucas, Margaret; Lin, Thomas; Hackbarth, Marcy L.; Proffitt, John H.; Lucas, David; Grever, Michael R.; Byrd JC Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood. 2004 Jan; 103(9):3278-3281.
  • Zhang, Liwen; Freitas, Michael, A; Wickham, Joseph; Parthun, Mark, R; Klisovic, Marko, I; Marcucci, Guido; Byrd JC Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry. Journal of the American Society for Mass Spectrometry. 2004 Jan; 15(1):77-86.
  • Marcucci, G; Stock, W; Dai, G; Klisovic, M, I; Maharry, K; Shen, T; Liu, S; Sher, D, A; Lucas, D; Zwiebel, A; Larson, R, A; Caligiuri, M, A; Bloomfield, C, D; Chan, K, K; Grever, M, R; Byrd JC G3139, a BCL-2 antisense oligo-nucleotide, in AML. Annals of Hematology. 2004 Jan; 83 Suppl 1 .
  • Lin, Thomas, S; Moran, Mollie; Lucas, Margaret; Waymer, Sharon; Jefferson, Sara; Fischer, Diane, B; Grever, Michael, R; Byrd JC Antibody therapy for chronic lymphocytic leukemia: a promising new modality. Hematology/oncology clinics of North America. 2004 Jan; 18(4):895-913, ix.
  • Lucas, D, M; Davis, M, E; Parthun, M, R; Mone, A, P; Kitada, S; Cunningham, K, D; Flax, E, L; Wickham, J; Reed, J, C; Byrd JC; Grever, M R The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004 Jan; 18(7):.
  • Byrd JC, Peterson B, Lawrence P, Saven A, Vardiman J, Larson R, Schiffer C A Phase II Study of Cladribine Treatment for Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 9211 Leukemia. 2003 Jan; 17 323-327.
  • Byrd JC Antibody therapy in chronic lymphocytic leukemia Clinical Advances in Hematology Oncology. 2003 Jan; 2 89-90.
  • Castagna L, Sarina B, Santoro A, Byrd JC, Rai K, Larson RA Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia Blood. 2003 Jan; 102 2309-2310.
  • Grever, Michael R.; Dewald, Gordon W.; Lucas, David M.; Neuberg, Donna S.; Baird, Maureen E.; Paternoster, Sarah F.; Brockman, Stephanie R.; Lozanski, Gerard; Rizouli, Vassiliki; Gribben, John G.; Flinn, Ian W.; Tallman, Martin S.; Kitada, Shinichi; Reed, John C.; Staudt, Louis M.; Paietta, Elisabeth; Byrd JC Zap-70 protein expression varies by interphase cytogenetic group and may predict disease progression to requirement of treatment among select genetic groups in patients with chronic lymphocytic leukemia (cll). Blood. 2003 Jan; 102(11):73a.
  • Eisenbeis, Charles, F; Caligiuri, Michael, A; Byrd JC Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma? Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Jan; 9(16 Pt 1):5810-2.
  • Pavletic, Steven Z.; Bociek, R. Gregory; Foran, James M.; Rubocki, Ronald J.; Kuszynski, Charles A.; Wisecarver, James L.; Hatcher, Lori; Lucas, David M.; Byrd JC; Grever, Michael R.; Joshi, Shantaram S.; Hardiman, Penny; Smith, Lynette M.; McGuire, Timothy R.; Bierman, Philip J.; Vose, Julie M.; Armitage, James O.; Talmadge, James E. Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. Transplantation (Hagerstown). 2003 Jan; 76(5):877-881.
  • Mone, Andrew P.; Cheney, Carolyn; Huang, Peng; Pelicano, Helene; Green, Jennifer; Tso, J. Yun; Johnson, Amy; Byrd JC Hu1d10 activates both death and survival pathways in primary human chronic lymphocytic leukemia cells: Hu1d10 induced reactive oxygen species activate the Akt survival pathway. Blood. 2003 Jan; 102(11):438a.
  • Blum, William G.; Bolwell, Brian J.; Farag, Sherif S.; Lin, Thomas S.; Avalos, Belinda R.; Penza, Sam L.; Marcucci, Guido; Byrd JC; Kalaycio, Matt E.; Sobecks, Ronald M.; Pohlman, Brad; Brown, Stacey; Elder, Patrick J.; Copelan, Edward A. Only those refractory Aml patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation. Blood. 2003 Jan; 102(11):488a.
  • Xiao, Jim, J; Byrd JC; Marcucci, Guido; Grever, Michael; Chan, Kenneth K Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid communications in mass spectrometry : RCM. 2003 Jan; 17(8):757-66.
  • Kasamon, Yvette L.; Byrd JC; Grever, Michael R.; Diehl, Louis F.; Lucas, Margaret S.; Garrett, Elizabeth S.; Flinn, Ian W. Il-2 does not protect against fludarabine and cyclophosphamide induced immunosuppression. Blood. 2003 Jan; 102(11):637a.
  • Byrd JC; Lucas, David, M; Mone, Andrew, P; Kitner, Joshua, B; Drabick, Joseph, J; Grever, Michael R KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood. 2003 Jan; 101(11):4547-50.
  • Byrd JC; Smith, Lisa; Hackbarth, Marcy L.; Flinn, Ian W.; Young, Donn; Proffitt, John H.; Heerema, Nyla A. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Research. 2003 Jan; 63(1):36-38.
  • Byrd JC; Smith, Lisa; Hackbarth, Marcy, L; Flinn, Ian, W; Young, Donn; Proffitt, John, H; Heerema, Nyla A Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer research. 2003 Jan; 63(1):36-8.
  • Marcucci, Guido; Byrd JC; Dai, Guowei; Klisovic, Marko I.; Kourlas, Peter J.; Young, Donn C.; Cataland, Spero R.; Fisher, Diane B.; Lucas, David; Chan, Kenneth K.; Porcu, Pierluigi; Lin, Zhong-Pin; Farag, Sherif F.; Frankel, Stanley R.; Zwiebel, James A.; Kraut, Eric H.; Balcerzak, Stanley P.; Bloomfield, Clara D.; Grever, Michael R.; Caligiuri, Michael A. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003 Jan; 101(2):425-432.
  • Klisovic, M, I; Maghraby, E, A; Parthun, M, R; Guimond, M; Sklenar, A, R; Whitman, S, P; Chan, K, K; Murphy, T; Anon, J; Archer, K, J; Rush, L, J; Plass, C; Grever, M, R; Byrd JC; Marcucci, G Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 Jan; 17(2):.
  • Aron, Jennifer, L; Parthun, Mark, R; Marcucci, Guido; Kitada, Shinichi; Mone, Andrew, P; Davis, Melanie, E; Shen, Tiansheng; Murphy, Timothy; Wickham, Joseph; Kanakry, Chris; Lucas, David, M; Reed, John, C; Grever, Michael, R; Byrd JC Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood. 2003 Jan; 102(2):652-8.
  • Byrd JC; Lucas, David M.; Mone, Andrew P.; Kitner, Joshua B.; Drabick, Joseph J.; Grever, Michael R. Krn5500: A novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood. 2003 Jan; 101(11):4547-4550.
  • Marcucci, Guido; Dai, Guowei; Klisovic, Marko I.; Shen, Tiasheng; Liu, Shujun; Sher, Dorie A.; Lucas, David; Whitman, Susan P.; Vukosavljevic, Tamara; Zwiebel, James A.; Frankel, Stanley R.; Grever, Michael R.; Stock, Wendy; Chan, Kenneth K.; Byrd JC Pharmacologic and biologic assessment of Genasensetm (gns, oblimersen sodium), a pro-apoptotic to Bcl-2 oligonucleotide, in combination with daunorubicin and cytarabine: A phase I study in previously untreated elderly acute myeloid leukemia (aml). Blood. 2003 Jan; 102(11):874a.
  • Marcucci, Guido; Byrd JC; Dai, Guowei; Klisovic, Marko, I; Kourlas, Peter, J; Young, Donn, C; Cataland, Spero, R; Fisher, Diane, B; Lucas, David; Chan, Kenneth, K; Porcu, Pierluigi; Lin, Zhong-Pin; Farag, Sherif, F; Frankel, Stanley, R; Zwiebel, James, A; Kraut, Eric, H; Balcerzak, Stanley, P; Bloomfield, Clara, D; Grever, Michael, R; Caligiuri, Michael A Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003 Jan; 101(2):425-32.
  • Johnson, Amy, J; Mone, Andrew, P; Abhyankar, Vivek; Byrd JC Advances in the therapy of chronic lymphocytic leukemia. Current opinion in hematology. 2003 Jan; 10(4):297-305.
  • Lin, Thomas S.; Lucas, Margaret S.; Byrd JC Rituximab in B-cell chronic lymphocytic leukemia. Seminars in Oncology. 2003 Jan; 30(4):483-492.
  • Lin, Thomas, S; Lucas, Margaret, S; Byrd, John C Rituximab in B-cell chronic lymphocytic leukemia. Seminars in oncology. 2003 Jan; 30(4):483-92.
  • Lucas, David M.; Zhang, Liwen; Freitas, Michael A.; Wickham, Joseph; Parthun, Mark R.; Davis, Melanie E.; Marcucci, Guido; Byrd JC; Grever, Michael R. Ms-275 mediated apoptosis and generation of reactive oxygen species are caspase dependent in B-cell chronic lymphocytic leukemia (cll). Blood. 2003 Jan; 102(11):431a.
  • Lin, Thomas S.; Stock, Wendy; Lucas, Margaret S.; Porcu, Pierluigi; Abhyankar, Vivek V.; Jefferson, Sara K.; Briggs, Bruce; Wang, Hong; Cheney, Carolyn; Flinn, Ian W.; Grever, Michael R.; Dalton, James T.; Byrd JC A Phase I Dose Escalation Study of Apolizumab (hu1d10) Using a Stepped Up Dosing Schedule in Patients with Chronic Lymphocytic Leukemia (cll) and Acute Lymphocytic Leukemia (all). Blood. 2002 Jan; 100(11):Abstract No. 3167.
  • Lin, Thomas S.; Flinn, Ian W.; Lucas, Margaret S.; Sickler, Jennifer; Moran, Mollie E.; Porcu, Pierluigi; Lucas, David M.; Grever, Michael R.; Byrd JC Filgrastim and Alemtuzumab (campath-1h) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed Neutropenia. Blood. 2002 Jan; 100(11):Abstract No. 3168.
  • Marcucci, Guido; Stock, Wendy; Klisovic, Marko I.; Guimond, Martin; Sher, Dorie A.; Moran, Mollie; Zwiebel, James A.; Cataland, Spero R.; Kefauver, Cheryl; Chan, Kenneth K.; Frankel, Stanley R.; Grever, Michael R.; Byrd JC In Vivo Activity of Genasensetm (g3139) (gs), a Bcl-2 Antisense Oligonucleotide in Previously Untreated Patients (pts) >60 Years with Acute Myeloid Leukemia (aml): Initial Report of a Phase I Study in Combination with Daunorubicin and Blood. 2002 Jan; 100(11):Abstract No. 1307.
  • Lucas, David M.; Baird, Maureen E.; Byrd JC; Tschumper, Renee C.; Jelinek, Diane F.; Kitada, Shinichi; Reed, John C.; Rosenwald, Andreas; Staudt, Louis M.; Neuberg, Donna S.; Tallman, Martin S.; Flinn, Ian W.; Grever, Michael R. Zap70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin Vh Gene Mutational Status in Patients with B-cell Chronic Lymphocytic Leukemia (b-cll). Blood. 2002 Jan; 100(11):Abstract No. 1478.
  • Lucas, David M.; Davis, Melanie; Parthun, Mark R.; Mojica, Ron C.; Mone, Andrew P.; Zwiesler, Julie; Byrd JC; Grever, Michael R. Ms-275 Promotes Apoptosis in Cells from Patients with B-cell Chronic Lymphocytic Leukemia (b-cll) Concurrent with Inhibition of Histone Deactylase. Blood. 2002 Jan; 100(11):Abstract No. 1500.
  • Mone, Andrew P.; Lucas, David; Aron, Jennifer; Cheney, Carolyn; Johnson, Amy; Bains, Suneet K.; Tso, J. Y.; Weiner, George; Green, Jennifer; Grever, Michael; Byrd JC Hu1d10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia (cll) Cells: Justification for Combination Studies of Hu1d10 with Pi3 Kinase Inhibitors. Blood. 2002 Jan; 100(11):Abstract No. 1496.
  • Reed, John, C; Kitada, Shinichi; Kim, Youngsoo; Byrd JC Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Seminars in oncology. 2002 Jan; 29(1 Suppl 2):10-24.
  • Marcucci, Guido; Bruner, Rebecca J.; Binkley, Philip F.; Xiao, Jim; Chan, Kenneth K.; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Byrd JC; Grever, Michael Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (fr901228) in Acute Myeloid Leukemia (aml). Blood. 2002 Jan; 100(11):Abstract No. 317.
  • Lucas, David M.; Parthun, Mark R.; Mojica, Ronald D.; Mone, Andrew P.; Byrd JC; Grever, Michael R. Ms-275 reduces viability and induces changes in histone acetylation in cells from patients with B-cell chronic lymphocytic leukemia (b-cll) Proceedings of the American Association for Cancer Research Annual Meeting. 2002 Jan; 43 69.
  • Lin, Thomas S.; Molina, Arthur; Penza, Sam L.; Farag, Sherif S.; Avalos, Belinda R.; Grever, Michael R.; Copelan, Edward A.; Byrd JC Diffuse Alveolar Hemorrhage in Patients Undergoing Non-myeloablative Allogeneic Stem Cell Transplantation after Prior Autologous / Syngeneic Transplantation. Blood. 2002 Jan; 100(11):Abstract No. 5300.
  • Raval, Aparna; Rush, Laura J.; Funchain, Pauline; Flak, Erin; Davis, Melanie; Johnson, Amy J.; Byrd JC; Plass, Christoph Aberrant Dna Methylation in Chronic Lymphocytic Leukemia: A Role in Pathogenesis? Blood. 2002 Jan; 100(11):Abstract No. 1469.
  • Byrd JC Clonal lymphocytosis of uncertain significance (CLUS): What clues will CLUS yield? Blood. 2002 Jan; 100 227.
  • Kay, Neil, E; Hamblin, Terry, J; Jelinek, Diane, F; Dewald, Gordon, W; Byrd JC; Farag, Sherif; Lucas, Margaret; Lin, Thomas Chronic lymphocytic leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2002 Jan; 193-213.
  • Bruner, Rebecca J.; Marcucci, Guido; Binkley, Philip; Xiao, Jim; Chan, Kenneth; Parthun, Mark; Davis, Melanie; Fischer, Beth; Shank, Roshini; Moran, Mollie; Grever, Michael; Byrd JC Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (fr901228) in Fludarabine Refractory Chronic Lymphocytic Leukemia. Blood. 2002 Jan; 100(11):Abstract No. 1492.
  • Sooraj, Lakshmi Narayan; Marcucci, Guido; Byrd JC; Bruner, Rebecca J.; Fischer, Beth; Hatton, Patty; Grever, Michael R.; Binkley, Philip F. Cardiovascular Response to Depsipeptide: Absence of Cardiotoxicity in Human Recipients. Blood. 2002 Jan; 100(11):Abstract No. 4421.
  • Lin, Thomas S.; Elder, Patrick J.; Penza, Sam L.; Avalos, Belinda R.; Farag, Sherif S.; Molina, Arthur; Mrozek, Ewa; Belt, Patti S.; Porcu, Pierluigi; Marcucci, Guido; Byrd JC; Copelan, Edward A. Autologous Stem Cell Transplants Result in Better 5-year Overall, but Not Progression-free, Survival Than Allogeneic Transplants in Patients with Indolent Non-hodgkin's Lymphoma. Blood. 2002 Jan; 100(11):Abstract No. 2536.
  • Keating, Michael, J; Flinn, Ian; Jain, Vinay; Binet, Jacques-Louis; Hillmen, Peter; Byrd JC; Albitar, Maher; Brettman, Lee; Santabarbara, Pedro; Wacker, Bret; Rai, Kanti R Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 Jan; 99(10):3554-61.
  • Heinrich, Michael C.; Druker, Brian J.; Curtin, Peter T.; Paquette, Ronald; Sawyers, Charles L.; De Angelo, Daniel J.; Gilliland, Gary D.; Stone, Richard M.; Caliguiri, Michael A.; Byrd JC; Heaney, Mark L.; Nimer, Stephen D.; Romanko, Kevin P.; Lambing, Joe L.; Lokker, Nathalie A.; Giese, Neill A.; Gretler, Daniel D. A "first in Man" Study of the Safety and Pk/pd of an Oral Flt3 Inhibitor (mln518) in Patients with Aml or High Risk Myelodysplasia. Blood. 2002 Jan; 100(11):Abstract No. 1305.
  • Byrd JC; Grever, Michael R.; Flinn, Ian W.; Waselenko, Jamie K. Combination therapy for lymphoproliferative diseases Official Gazette of the United States Patent and Trademark Office Patents. 2001 Jan; 1252(2):.
  • Waselenko, Jamie K.; Grever, Michael R.; Shinn, Charlotte A.; Flinn, Ian W.; Byrd JC Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia Leukemia Research. 2001 Jan; 25(6):435-440.
  • Byrd JC; Peterson, Bercedis; Piro, Lawrence; Saven, Alan; Vardiman, James W.; Larson, Richard A.; Schiffer, Charles A. Cladribine has clinical activity in patients with fludarabine refractory chronic lymphocytic leukemia who lack pre-treatment cytopenias: Results from Calgb study 9211 Blood. 2001 Jan; 98(11 Part 1):634a.
  • Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards A, Clark B, Lucas MS, Schlossman R, Anderson KC, Byrd JC Serotherapy of Walderstrom’s macroglobulinemia Journal of Immunotherapy. 2001 Jan; 24 272-279.
  • Aron, Jennifer L.; Murphy, Timothy; Parthun, Mark R.; Bannerji, Rajat; Kanakry, Chris; Lucas, David; Flinn, Ian W.; Marcucci, Guido; Grever, Michael R.; Byrd JC The histone deacetylase inhibitor depsipeptide (fr901228) induces apoptosis via activation of the caspase 8 pathway concurrent with lysine specific acetylation in chronic lymphocytic leukemia cells Blood. 2001 Jan; 98(11 Part 1):807a-808a.
  • Bannerji, Rajat; Kitada, Shinichi; Flinn, Ian W.; Pearson, Michael; Lucas, David; Grever, Michael R.; Reed, John C.; Byrd JC Campath-1h antibody induces transmembrane signaling in vitro and in vivo in patients with chronic lymphocytic leukemia (cll) and promotes tumor clearance in part through caspase mediated apoptosis Blood. 2001 Jan; 98(11 Part 1):808a.
  • Maghraby, Eman A.; Murphy, Thimoty; Parthun, Mark R.; Klisovic, Marko; Sklenar, Amy; Archer, Kellie J.; Whitman, Susan; Grever, Michael R.; Caligiuri, Michael A.; Byrd JC; Marcucci, Guido Depsipeptide (fr901228) induces lysine-specific histone acetylation, differentiation and apoptosis in acute myeloid leukemia cells and demonstrates synergy with decitabine Blood. 2001 Jan; 98(11 Part 1):103a-104a.
  • Cataland, Spero R.; Lucas, Margaret; Byrd JC Antibody therapy of acute and chronic leukemias Current Pharmaceutical Biotechnology. 2001 Jan; 2(4):357-367.
  • Rosenwald, Andreas; Alizadeh, Ash A.; Widhopf, George; Simon, Richard; Davis, R. Eric; Yu, Xin; Yang, Liming; Pickeral, Oxana K.; Rassenti, Laura Z.; Powell, John; Botstein, David; Byrd JC; Grever, Michael R.; Cheson, Bruce D.; Chiorazzi, Nicholas; Wilson, Wyndham H.; Kipps, Thomas J.; Brown, Patrick O.; Staudt, Louis M. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia Journal of Experimental Medicine. 2001 Jan; 194(11):1639-1647.
  • Byrd JC; Shinn, Charlotte; Willis, Carl R.; Flinn, Ian W.; Lehman, Theresa; Sausville, Edward; Lucas, David; Grever, Michael R. Ucn-01 induces cytotoxicity toward human Cll cells through a p53-independent mechanism Experimental Hematology (Charlottesville). 2001 Jan; 29(6):703-708.
  • Baird, Maureen E.; Lucas, David M.; Mone, Andrew P.; Waymer, Sharon; Warrell, Raymond P.; Byrd JC; Grever, Michael R. G3139 promotes release of Il-8 by chronic lymphocytic leukemia cells cultured in vitro: Potential implications for therapeutic use Blood. 2001 Jan; 98(11 Part 2):281b.
  • Link, Brian K.; Wang, Hong; Byrd JC; Leonard, John P.; Davis, Thomas A.; Flinn, Ian; Hall, William C.; Turner, John F.; Bowles, Julie; Shannon, Mary; Levitt, Daniel; Weiner, George J. Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-hla-dr monoclonal antibody Remitogentm (hu1d10) Blood. 2001 Jan; 98(11 Part 2):244b.
  • Byrd JC; Murphy, Timothy; Howard, Robin S.; Lucas, Margaret S.; Goodrich, Amy; Park, Kathy; Pearson, Michael; Waselenko, Jamie K.; Ling, Geoffrey; Grever, Michael R.; Grillo-Lopez, Antonio J.; Rosenberg, Jay; Kunkel, Lori; Flinn, Ian W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity Journal of Clinical Oncology. 2001 Jan; 19(8):2153-2164.
  • Byrd JC, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD Recent Gentic Studies of Adult Patients with Acute Myeloid Leukemia Performed by the Cancer and Leukemia Group B.: Acute Leukemias VIII Prognostic Factors and Treatment Stragegies Springer-Verlag. 2001 Jan; 449-456.
  • Bloomfield CD, Farag SS, Mrozek K, Byrd JC, Dodge RK, Archer KJ, Whitman S, Larson RA, Carrol RJ, Caligiuri MA Cytogenetics for Treatment Stratification in Adult Acute Myeloid Leukemia (AML) Annals of Hematology. 2001 Jan; .
  • Byrd JC; Peterson, Bercedis L.; Park, Kathy; Morrison, Vicky L.; Vardiman, James W.; Jacobson, Robert; Rai, Kanti; Larson, Richard A. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (cll) patients: Results from Calgb 9712 Blood. 2001 Jan; 98(11 Part 1):772a.
  • Byrd JC; Mrozek, Krzysztof; Dodge, Richard; Carroll, Andrew J.; Edwards, Colin; Pettenati, Mark J.; Patil, Shivanand R.; Larson, Richard A.; Bloomfield, Clara D. Pre-treatment cytogenetics predict initial induction success and overall survival in adult patients with de novo acute myeloid leukemia: Results from Calgb 8461 Blood. 2001 Jan; 98(11 Part 1):457a.
  • Waselenko, J, K; Shinn, C, A; Willis, C, R; Flinn, I, W; Grever, M, R; Byrd JC Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cells. Leukemia & lymphoma. 2001 Jan; 42(5):.
  • Link, Brian K.; Kahl, Brad; Czuczman, Myron; Powell, Bayard L.; Bartlett, Nancy; Leonard, John P.; Ansell, Stephan; Porcu, Perliuigi; Byrd JC; Lazarus, Hillard M.; Flinn, Ian; Jones, Gary J.; Levitt, Dan; Hall, William C.; Weiner, George J. A phase Ii study of Remitogentm (hu1d10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/malt B-cell lymphoma Blood. 2001 Jan; 98(11 Part 1):606a.
  • Lucas, Margaret S.; Flinn, Ian W.; Goodrich, Amy L.; Murphy, Timothy; Park, Kathy; Grever, Michael R.; Lehman, Theresa; Byrd JC Tnf-alpha and Tnf-beta promoter polymorphisms may relate to response to rituximab therapy Blood. 2001 Jan; 98(11 Part 1):634a.
  • Ales, N; Flynn, J; Byrd JC Novel presentation of acute myelogenous leukemia as symptomatic galactorrhea. Annals of internal medicine. 2001 Jan; 135(4):.
  • Marcucci, Guido; Byrd JC; Cataland, Spero R.; Fisher, Diane B.; Lucas, David; Chan, Kenneth K.; Klisovic, Marko; Young, Donn C.; Didier, Lisa A.; Balcerzak, Stanley P.; Frankel, Stanley R.; Kraut, Eric H.; Bloomfield, Clara D.; Grever, Michael R.; Caligiuri, Michael A. Clinical and biological activity of Genasensetm (g3139, Genta, Inc.) (gs), a bcl-2 antisense, in refractory (ref) or relapsed (rel) acute leukemia (al): A phase I study Blood. 2001 Jan; 98(11 Part 2):216b.
  • Lucas, David M.; Baird, Maureen E.; Neuberg, Donna S.; Tallman, Martin S.; Flinn, Ian W.; Byrd JC; Grever, Michael R. Importance of culture conditions for in vitro chemosensitivity assessment in Chronic Lymphocytic Leukemia cells: Preliminary results from laboratory studies, Eastern Cooperative Oncology Group Study 2997 Blood. 2001 Jan; 98(11 Part 2):284b.
  • Porcu, Pierluigi; Farag, Sherif; Marcucci, Guido; Avalos, Belinda; Rhoades, Chris; Fisher, Beth; Byrd JC; Grever, Michael R.; Caligiuri, Michael A. Phase I trial of interleukin-2 (il-2) and rituximab in patients (pts) with relapsed or refractory B-cell lymphomas (r/r-bcl) Blood. 2001 Jan; 98(11 Part 2):245b.
  • Byrd JC; Shinn, C; Willis, C, R; Flinn, I, W; Lehman, T; Sausville, E; Lucas, D; Grever, M R UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Experimental hematology. 2001 Jan; 29(6):.
  • Bannerji, Rajat; Byrd JC Update on the biology of chronic lymphocytic leukemia Current Opinion in Oncology. 2000 Jan; 12(1):22-29.
  • Ales, Noel C.; Helman, Donald L.; Shorr, Andrew F.; Byrd JC Fludarabine associated pulmonary toxicity in chronic lymphoproliferative disorders: A case series Blood. 2000 Jan; 96(11 Part 1):756a-757a.
  • Byrd JC, Bannerji R, Perkins J New Treatment Approaches for Chronic Lymphocytic Leukemia Oncology Review. 2000 Jan; .
  • Murphy, Timothy J.; Shinn, Charlotte; Grever, Michael R.; Byrd JC Depsipeptide induces histone acetylation and promotes apoptosis in human acute myelogenous leukemia cells with the t(8;21)(q22;q22) translocation Blood. 2000 Jan; 96(11 Part 2):214b.
  • Flinn, Ian W.; Goodman, Steve; Post, Linda; Jamison, Janet; Miller, Carole B.; Gore, Steve; Diehl, Louis; Willis, Carl; Ambinder, Richard F.; Byrd JC Liposomal daunorubicin with cyclophosphamide, vincristine, and prednisone (cop-x) in advanced non-hodgkin's lymphoma Cancer Investigation. 2000 Jan; 18(SUPPL. 1):15-16.
  • Waselenko JK, Grever MR, Beer M, Byrd JC A Phase II Study of Chlorambucil and Pentostatin in B-cell Chronic Lymphocytic Leukemia Seminars in Oncology. 2000 Jan; 27 44-51.
  • Flinn, Ian W.; Byrd JC; Morrison, Candis; Jamison, Janet; Diehl, Louis F.; Murphy, Timothy; Piantadosi, Steve; Seifter, Eric; Ambinder, Richard F.; Vogelsang, Georgia; Grever, Michael R. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood. 2000 Jan; 96(1):71-75.
  • Byrd JC; Waselenko, Jamie K.; Keating, Michael; Rai, Kanti; Grever, Michael R. Novel therapies for chronic lymphocytic leukemia in the 21st century Seminars in Oncology. 2000 Jan; 27(5):587-597.
  • Waselenko, J, K; Grever, M, R; Beer, M; Lucas, M, A; Byrd JC Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Seminars in oncology. 2000 Jan; 27(2 Suppl 5):.
  • Waselenko, Jamie K.; Grever, Michael R.; Beer, Mario; Lucas, Margaret A.; Byrd JC Pentostatin (nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia Seminars in Oncology. 2000 Jan; 27(2 Suppl. 5):44-51.
  • Byrd JC; Grever, Michael R.; Waselenko, Jamie K.; Willis, Carl R.; Park, Kathy; Goodrich, Amy; Lucas, Margaret A.; Shinn, Charlotte; Flinn, Ian W. Theophylline, pentostatin (nipent), and chlorambucil: A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders Seminars in Oncology. 2000 Jan; 27(2 Suppl. 5):37-40.
  • Byrd JC; Grever MR; Waselenko JK; Willis CR; Park K; Goodrich A; Lucas MA; Shinn C; Flinn IW Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. Seminars in oncology. 2000 Jan; 27(2 Suppl 5):.
  • Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger D, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Boststein D, Brown PO, Staudt LM Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling Nature. 2000 Jan; 403 503-511.
  • Waselenko, Jamie K.; Burrows, Ann; Lucas, Margaret; Ekstrand, John R.; Myhand, Rick; Lee, Nicole; Edenfield, William J.; Byrd JC Low dose recombinent interleukin 2 (ril-2) following high-dose chemotherapy (hdc) and autologous peripheral blood stem cell transplantation (pbsct) in patients with chronic lymphocytic leukemia (cll), mantle cell (mcl), and follicular lymphoma Blood. 2000 Jan; 96(11 Part 2):350b.
  • Widhopf, George F.; Marathe, Chaitra M.; Rassenti, Laura Z.; Byrd JC; Flinn, Ian W.; Gribben, John G.; Kipps, Thomas J. Lack of correlation between immunoglobulin somatic mutation and expression of Cd38 in chronic lymphocytic leukemia Blood. 2000 Jan; 96(11 Part 1):367a.
  • Byrd JC; Grever, Michael R.; Davis, Brad; Lucas, Margaret S.; Park, Kathy; Goodrich, Amy; Morrison, Candice; Murphy, Timothy; Kunkel, Lori; Grillo-Lopez, Antonio; Waselenko, Jamie K.; Flinn, Ian W. Phase I/ii study of thrice weekly rituximab in chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll): A feasible and active regimen Blood. 1999 Jan; 94(10 SUPPL. 1 PART 1):704a-705a.
  • Byrd JC; Waselenko, Jamie K.; Maneatis, Thomas J.; Murphy, Timothy; Ward, Frank T.; Monahan, Brian P.; Sipe, Melissa A.; Donegan, Sarah; White, Christine A. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance Journal of Clinical Oncology. 1999 Jan; 17(3):791-795.
  • Byrd JC; Shinn, Charlotte A.; Jansure, Jenny; Hydom, Chris; Pearson, Michael D.; Flinn, Ian W.; Grever, Michael R. Campath-1h induces apoptosis in human chronic lymphocytic leukemia cells (cll) in vitro independent of complement mediated lysis or Fcgamma receptor ligation Blood. 1999 Jan; 94(10 SUPPL. 1 PART 1):126a.
  • Byrd JC; Willis, Carl R.; Waselenko, Jamie K.; Park, Kathy; Goodrich, Amy; Morrison, Candice; Lucas, Margaret S.; Shinn, Charlotte; Diehl, Louis F.; Grever, Michael R.; Flinn, Ian W. Theophylline, pentostatin, and chlorambucil; a dose escalation study to modulate intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders Blood. 1999 Jan; 94(10 SUPPL. 1 PART 2):308b.
  • Byrd JC; Shinn, Charlotte A.; Pearson, Michael D.; Flinn, Ian W.; Link, Brian K.; Wang, Hong; Weiner, George; Grever, Michael R. Hu1d10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells (cll) independent of compliment mediated lysis but requires Fcgamma receptor ligation Blood. 1999 Jan; 94(10 SUPPL. 1 PART 1):314a.
  • Byrd JC; Shinn, Charlotte; Ravi, Rajani; Willis, Carl R.; Waselenko, Jamie K.; Flinn, Ian W.; Dawson, Nancy A.; Grever, Michael R. Depsipeptide (fr901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells Blood. 1999 Jan; 94(4):1401-1408.
  • Willis, Carl; Byrd JC; Shinn, Charlotte; Flinn, Ian W.; Grever, Michael R. Ucn-01 chemosensitizes human B-chronic lymphocytic leukemia (b-cll) cells to the effects of fludarabine Blood. 1999 Jan; 94(10 SUPPL. 1 PART 1):127a.
  • Pearson, Michael D.; Shinn, Charlotte; Grever, Michael R.; Flinn, Ian W.; Byrd JC Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells (cll) independent of complement mediated lysis but requires Fcgamma receptor ligation Blood. 1999 Jan; 94(10 SUPPL. 1 PART 2):313b.
  • Perkins, Jeremy G.; Flynn, Joseph M.; Byrd JC Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma (cll/sll): Implications for clinical trials in this patient population Blood. 1999 Jan; 94(10 SUPPL. 1 PART 1):540a.
  • Flynn, Joseph M.; Howard, Robin S.; Byrd JC Second malignancies in B-cell chronic lymphocytic leukemia (cll): Association with Cll but no additional impact with fludarabine or alkylator treatment Blood. 1999 Jan; 94(10 SUPPL. 1 PART 2):298b.
  • Murphy, Timothy J.; Ling, Geoffrey; Flynn, Ian W.; Lucas, Margaret S.; Park, Kathy; Goodrich, A.; Grever, Michael R.; Byrd JC Infusion-related events following rituximab therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll): Association with inflammatory cytokines Blood. 1999 Jan; 94(10 SUPPL. 1 PART 1):312a.
  • Byrd JC; Rai, Kanti R.; Sausville, Edward A.; Grever, Michael R. Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals Seminars in Oncology. 1998 Jan; 25(1):65-74.
  • Byrd JC, Weiss RB In Response to: Hemolytic Anemia and Fludarabine Treatment Journal of Clinical Oncology. 1998 Jan; 16 3209-3210.
  • Wortmann, Glenn W.; Aronson, Naomi E.; Byrd JC; Grever, Michael R.; Oster, Charles N. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis Clinical Infectious Diseases. 1998 Jan; 27(3):509-512.
  • Byrd JC, Flinn IW, Grever MR Introduction: Chronic Lymphocytic Leukemia Seminars in Oncology. 1998 Jan; 25 4-5.
  • Byrd JC; Shinn, Charlotte; Waselenko, Jamie K.; Fuchs, Ephraim J.; Lehman, Teresa A.; Nguyen, Phuong L.; Flinn, Ian W.; Diehl, Louis F.; Sausville, Edward; Grever, Michael R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood. 1998 Jan; 92(10):3804-3816.
  • Byrd JC, Weiss RB Recurrent granulocytic sarcoma. An Unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translation and blast expression of the neural cell adhesion molecule 8;21 chromosomal translocation and blast expression of the neural cell adhesion molecule Cancer. 1994 Jan; 8(73):2107-2112.